Ibudilast, the company’s lead drug development candidate for neurological conditions and pain, will be covered for use in drug addition and to enhance opioid analgesia in acute pain settings.
The patent is based on a preclinical study from pain researchers at the University of Colorado, which claims ibudilast uses four inhibitors to treat or prevent acute pain in combination with opioids, such as morphine or oxycodone.
More Articles on Anesthesia:
Anesthesiologist Named Southern Medical Association President
CMS Releases Locale Anesthesia Conversion Factors
Anesthesia Managed Care Contract Rates: Thoughts From Tony Mira
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
